Yudai Ishiyama presents a restricted mean survival time analysis of four IO combination regimens in advanced clear cell RCC. Using digitized Kaplan-Meier data from CheckMate 214, ...
ASCO 2024 Bladder Cancer ASCO 2024: What Is Variant Histology Urothelial Cancer and What Are the Available Treatment Options? ASCO 2024: Phase II Trial of Intravesical Camrelizumab in BCG-Unresponsive ...
Cristina Suárez describes LITESPARK-033, a phase 3 trial addressing an unmet need in patients who progress during or within 24 months after adjuvant pembrolizumab for clear cell renal cell carcinoma.
Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
AUA 2026, BCG naive and BCG-Exposed High-Risk Non–muscle Invasive Bladder Cancer, Intravesical MK-3120, anti–Nectin-4 monoclonal antibody, MK-3120 I-VESIC.
(UroToday.com) The 2023 ASCO annual meeting included a kidney cancer session, featuring a presentation by Dr. Brian Rini discussing the 5-year analysis of KEYNOTE-426, assessing pembrolizumab + ...
(UroToday.com) The Friday afternoon plenary session opened with the prestigious John K. Lattimer Lecture, one of the AUA’s most prestigious lectureships honoring Dr. John K. Lattimer, a pioneering ...
(UroToday.com) The 2024 American Society of Clinical Oncology (ASCO) annual meeting held in Chicago, IL between May 31 and June 4 was host to the Poster Session: Genitourinary Cancer: Kidney and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results